Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Current Assets (2016 - 2025)

Historic Current Assets for Karyopharm Therapeutics (KPTI) over the last 14 years, with Q4 2025 value amounting to $103.1 million.

  • Karyopharm Therapeutics' Current Assets fell 3407.6% to $103.1 million in Q4 2025 from the same period last year, while for Dec 2025 it was $103.1 million, marking a year-over-year decrease of 3407.6%. This contributed to the annual value of $103.1 million for FY2025, which is 3407.6% down from last year.
  • According to the latest figures from Q4 2025, Karyopharm Therapeutics' Current Assets is $103.1 million, which was down 3407.6% from $89.7 million recorded in Q3 2025.
  • In the past 5 years, Karyopharm Therapeutics' Current Assets ranged from a high of $350.2 million in Q4 2022 and a low of $89.7 million during Q3 2025
  • Its 5-year average for Current Assets is $220.2 million, with a median of $237.8 million in 2021.
  • Per our database at Business Quant, Karyopharm Therapeutics' Current Assets soared by 2705.17% in 2022 and then plummeted by 5306.9% in 2025.
  • Karyopharm Therapeutics' Current Assets (Quarter) stood at $275.6 million in 2021, then increased by 27.05% to $350.2 million in 2022, then plummeted by 33.2% to $233.9 million in 2023, then crashed by 33.11% to $156.5 million in 2024, then tumbled by 34.08% to $103.1 million in 2025.
  • Its Current Assets was $103.1 million in Q4 2025, compared to $89.7 million in Q3 2025 and $97.9 million in Q2 2025.